Shire Receives VYVANSE Paragraph IV Notice Letter

Shire plc SHPGY announces that its subsidiary Shire LLC has received a Paragraph IV Notice Letter from Sandoz Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of all strengths of lisdexamfetamine dimesylate capsules, VYVANSE. This is the first Paragraph IV Notice Letter directed to VYVANSE received by the company. VYVANSE is protected by sixteen FDA Orange Book listed patents, all of which expire in 2023.